ClinicalTrials.gg
Not yet recruitingNCT07913997ADHD DextEggUpdated Nov 5, 2026

Cognitive-Motor Training With the DextEgg in Children With ADHD

An interventional study of Cognitive-motor DextEgg training and Motor-only DextEgg training in Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Manuela Pastore-Wapp. Not yet recruiting. Open to participants aged 8 Years to 13 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Manuela Pastore-Wapp · Not applicable, Interventional, and Treatment

Updated Nov 3, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
8 Years to 13 Years
Sex
All
01

Study summary

Attention Deficit Hyperactivity Disorder (ADHD) is frequently accompanied by deficits in executive functions and fine motor skills, which affect daily activities, academic performance, and health-related quality of life. The DextEgg is a gamified hand-training device with motion and pressure sensors that connects to a tablet app and allows fine motor exercises to be combined with cognitive demands (inhibition, working memory, cognitive flexibility). This single-center randomized controlled trial evaluates whether a 4-week home-based cognitive-motor training with the DextEgg improves fine motor skills and executive functions in children aged 8 to 12 years with ADHD, compared with a motor-only DextEgg training of identical dose. Fifty children will be randomized 1:1 and complete 20 home-based sessions (5 per week, 35 minutes each). Assessments take place at baseline, after the intervention, and at 3-month follow-up.

02

Conditions studied

  • Attention Deficit Hyperactivity Disorder (ADHD)

Keywords

  • ADHD
  • Children
  • fine motor skills
  • manual dexterity
  • executive functions
  • cognitive-motor training
03

In context

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 296 are open to participants now.

This study's planned enrollment of 50 is below the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.

Browse Attention Deficit Disorder with Hyperactivity studies →

Lead sponsor

This is the only study on the registry with Manuela Pastore-Wapp as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 8 years 0 months to 12 years 11 months
  • Clinical ADHD diagnosis according to , confirmed by a physician or psychologist
  • Written by legal guardian and assent by the child
  • Caregiver-reported difficulties in fine motor tasks (e.g., handwriting, tying shoes)
  • Caregiver-reported executive functioning difficulties in daily life

Exclusion criteria

Exclusion Criteria:

  • Any other significant neurological, developmental, or psychiatric condition that could affect fine motor or cognitive functioning
  • Participation in another intervention study during the study period
  • Inability to follow study procedures due to language difficulties or other barriers
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Cognitive-Motor DextEgg Training

    20 home-based sessions over 4 weeks (5x/week, 35 min): finger-specific dexterity exercises with embedded cognitive challenges (inhibition, working memory, cognitive flexibility), adaptive difficulty

    Behavioral: Cognitive-motor DextEgg training

  • Active comparator
    Motor-Only DextEgg Training

    Same schedule, device and fine motor tasks, but without embedded cognitive challenge

    Behavioral: Motor-only DextEgg training

Interventions

  • BehavioralCognitive-motor DextEgg training

    Gamified, app-guided home training with the DextEgg (sensor-equipped hand trainer connected via Bluetooth to a tablet) combining fine motor tasks (tapping, squeezing, rolling) with inhibition, working memory and cognitive-flexibility demands. Other names: Smart Sensor Egg (SSE).

  • BehavioralMotor-only DextEgg training

    Identical fine motor sequences with the DextEgg without dual-task or rule-switching elements; controls for device use, motor activity and training time.

06

What researchers measure

Primary outcomes

  1. Fine motor skills (M-ABC-3 fine motor coordination)

    Movement Assessment Battery for Children, 3rd edition, fine motor coordination subscale (placing pegs, threading lace, drawing trail)

    Time frame: Baseline, post-intervention (week 5), 3-month follow-up

Secondary outcomes

  1. Functional dexterity

    Functional Dexterity Test (FDT)

    Time frame: Baseline, post-intervention (week 5), 3-month follow-up

  2. Inhibitory control

    D-KEFS Color Word Interference Test, Part III

    Time frame: Baseline, post-intervention (week 5), 3-month follow-up

  3. Cognitive flexibility

    D-KEFS Color Word Interference Test, Part IV

    Time frame: Baseline, post-intervention (week 5), 3-month follow-up

  4. Verbal working memory

    WISC-V Digit Span (forward and backward)

    Time frame: Baseline, post-intervention (week 5), 3-month follow-up

  5. Visual working memory

    WISC-V Picture Span

    Time frame: Baseline, post-intervention (week 5), 3-month follow-up

  6. Attention

    TAP subtests Go/No-Go and Divided Attention

    Time frame: Baseline, post-intervention (week 5), 3-month follow-up

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2028, 20 months later.

Of 479 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 20 months is below that.

Counting every sponsor, half of 510 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 3, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Oct 31, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 3, 2026
Show all 2 updates
  1. Nov 5, 2026
    Minor edits only
    + 3 other changes: verification date, conditions and data sharing statement
  2. Nov 3, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07913997
Lead sponsor
Manuela Pastore-Wapp
Collaborators
University of Bern
Responsible party
Manuela Pastore-Wapp (Senior Researcher, University of Bern) — Sponsor-investigator
First posted
Nov 3, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jul 31, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Manuela Pastore-Wapp, PhD
Contact
manuela.pastore-wapp@unibe.ch
0412057220

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion